Clinical Trials
62
Trial Phases
4 Phases
Drug Approvals
160
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (51 trials with phase data)• Click on a phase to view related trials
Treprostinil in Newborns With Pulmonary Hypertension; a Non-Interventional Study to Collect Data on Drug Utilization, Safety, and Effectiveness
- Conditions
- Persistent Pulmonary Hypertension of Newborn
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2025-09-03
- Lead Sponsor
- Ferrer Internacional S.A.
- Target Recruit Count
- 60
- Registration Number
- NCT06499363
- Locations
- 🇫🇷
CHU Lyon (HCL) - Hopital Femme Mère Enfant, Bron, France
🇫🇷Réanimation néonatale CHU Grenoble Alpes - Hôpital Couple Enfant, Grenoble, France
🇫🇷CHU Lille - Clinique de Néonatalogie, Lille, France
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
- Conditions
- Progressive Supranuclear Palsy
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2025-09-03
- Lead Sponsor
- Ferrer Internacional S.A.
- Target Recruit Count
- 220
- Registration Number
- NCT06355531
- Locations
- 🇺🇸
The Neurology Center of Southern California - Carlsbad, Carlsbad, California, United States
🇺🇸UCSF Weill Institute for Neurosciences, San Francisco, California, United States
🇺🇸Rocky Mountain Movement Disorders Center, Denver, Colorado, United States
Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Ferrer Internacional S.A.
- Target Recruit Count
- 201
- Registration Number
- NCT05866926
- Locations
- 🇪🇸
Hospital Universitari de Bellvitge, Barcelona, Spain
Inhaled Treprostinil Expanded Access Program in Pulmonary Hypertension Associated With Interstitial Lung Disease
- Conditions
- Pulmonary HypertensionInterstitial Lung DiseaseCombined Pulmonary Fibrosis and Emphysema
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Ferrer Internacional S.A.
- Registration Number
- NCT05572996
Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Ferrer Internacional S.A.
- Target Recruit Count
- 300
- Registration Number
- NCT05178810
- Locations
- 🇧🇪
University Hospitals Leuven, Leuven, Belgium
🇫🇷CHRU de Lille - Hôpital Roger Salengro, Lille, France
🇫🇷CHU de Limoges - Hôpital Dupuytren, Limoges, France
- Prev
- 1
- 2
- 3
- 4
- 5
- Next